Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC lowered its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 43.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 524,814 shares of the biopharmaceutical company’s stock after selling 399,619 shares during the quarter. Hsbc Holdings PLC’s holdings in Royalty Pharma were worth $13,813,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in RPRX. Versant Capital Management Inc increased its position in shares of Royalty Pharma by 5,215.0% during the second quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 1,043 shares in the last quarter. Gladius Capital Management LP purchased a new stake in shares of Royalty Pharma during the second quarter worth $32,000. Fidelis Capital Partners LLC acquired a new stake in shares of Royalty Pharma in the first quarter valued at about $46,000. GAMMA Investing LLC lifted its stake in shares of Royalty Pharma by 172.5% in the first quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,037 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in Royalty Pharma by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 802 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Trading Down 1.6 %

Shares of Royalty Pharma stock opened at $27.54 on Monday. Royalty Pharma plc has a fifty-two week low of $25.20 and a fifty-two week high of $31.66. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35. The firm has a market capitalization of $16.45 billion, a price-to-earnings ratio of 20.55, a PEG ratio of 4.17 and a beta of 0.46. The stock has a 50 day moving average of $28.00 and a 200 day moving average of $27.98.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. The business had revenue of $537.00 million during the quarter, compared to analysts’ expectations of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same period in the prior year, the business posted $0.85 EPS. As a group, research analysts predict that Royalty Pharma plc will post 4.04 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 13th. Stockholders of record on Friday, August 16th were paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.05%. The ex-dividend date of this dividend was Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is 62.69%.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, September 17th. Morgan Stanley boosted their price objective on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, July 11th. The Goldman Sachs Group raised their target price on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Finally, UBS Group cut shares of Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price target on the stock. in a research report on Monday, June 3rd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Royalty Pharma has an average rating of “Moderate Buy” and a consensus target price of $42.00.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.